Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients

Journal of Bone and Mineral Metabolism

Volumn 21, Issue 3, 2003, Pages 166-171

  Watanabe, Sumiyo ^a   Takeuchi, Yasuhiro ^a   Fukumoto, Seiji ^a   Fujita, Hiroko ^b   Nakano, Tadasumi ^b   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Metropolitan Tama Geriatric Hospital   (Japan)

Author keywords

Bone mineral density; Diabetes mellitus; Leptin; Thiazolidinedione; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; GLUCOSE; HEMOGLOBIN A1C; LEPTIN; MARKER; TROGLITAZONE; ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; COLLAGEN; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; GLYCOSYLATED HEMOGLOBIN; PEPTIDE;

AGED; ARTICLE; BODY FAT; BODY MASS; BONE DENSITY; BONE MASS; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; ETHNIC GROUP; FEMALE; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; DRUG EFFECT; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE DENSITY; CHROMANS; COLLAGEN; COLLAGEN TYPE I; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LEPTIN; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 0642367440     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007740300026     Document Type: Article

References (32)

1. Schwartz A, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38
2. Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S, Matsumoto T (1997) Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 82:2915-2920
3. Garnero P, Delmas PD (1998) Biochemical markers of bone turnover. Applications for osteoporosis. Endocrinol Metab Clin N Am 27:303-323
4. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185
5. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW (1998) Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 83:3169-3176
6. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S (1997) Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153
7. Beresford J (1989) Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop Res 240:270-280
8. Yamaguchi A, Kahn AJ (1991) Clonal osteogenic cell lines express myogenic and adipocytic development potential. Calcif Tissue Int 49:221-225
9. Asahina I, Sampath TK, Hauschka PV (1996) Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp Cell Res 222: 38-47
10. Prockop D (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74
11. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y (1999) Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060-5065
12. Gimble J, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC (1996) Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087-1094
13. 2 inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. Bone (NY) 27:769-776
14. Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi Y (1999) Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795-801
15. Kallen C, Lazar MA (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93:5793-5796
16. De Vos P, Lefebvre A-M, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 98:1004-1009
17. Nolan JJ, Olefsky JM, Nyce MR, Considine RV, Caro JF (1996) Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes 45:1276-1278
18. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207
19. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL (1996) Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295
20. Edelstein S, Barrett-Connor E (1993) Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol 138:160-169
21. Chen Z, Lohman TG, Stini WA, Ritenbaugh C, Aickin M (1997) Fat or lean tissue mass: which one is the major determinant of bone mineral mass in healthy postmenopausal women? J Bone Miner Res 12:144-151
22. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV (1996) Decreased cerebrospinal fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 348: 159-161
23. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature (Lond) 395:763-770
24. Goulding A, Taylor RW (1998) Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 63:456-458
25. Rauch F, Blum WF, Klein K, Allolio B, Schonau E (1998) Does leptin have an effect on bone in adult women? Calcif Tissue Int 63:453-455
26. Odabasi E, Ozata M, Turan M, Bingol N, Yonem A, Cakir B, Kutlu M, Ozdemir IC (2000) Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol 142: 170-173
27. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M (1998) Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21: 1470-1474
28. Pi-Sunyer FX, Laferrere B, Aronne LJ, Bray GA (1999) Therapeutic controversy: obesity - a modern-day epidemic. J Clin Endocrinol Metab 84:3-12
29. Prigeon RL, Kahn SE, Porte D Jr (1998) Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:819-823
30. Auwerx J, Staels B (1998) Leptin. Lancet 351:737-342
31. Ogueh O, Sooranna S, Nicolaides KH, Johnson MR (1997) The relationship between leptin concentration and bone metabolism in the human fetus. J Clin Endocrinol Metab 85:1997-1999
32. Takeda S, Karsenty G (2001) Central control of bone formation. J Bone Miner Metab 19:195-198